Friday, December 14, 2018
Home Research & Development

Research & Development

Disease Activity in Circulating Tumor DNA Predicts Melanoma Progression

Circulating cancer biomarkers provide valuable information in detecting and diagnosing cancer. They may also help in predicting patient outcomes and treatment response. However, melanoma currently lacks a reliable blood‐based biomarker of disease activity. But researchers believe that circulating tumor DNA (ctDNA) may fill this role. According to the National Cancer Institute (NCI), there were 91,270 new cases of melanoma in...

Breast Cancers Recruit Cells from Bone Marrow to Enhance their Growth

Researchers at the Sackler School of Medicine, Tel Aviv University, in Israel have discovered that breast tumors can boost their own growth by recruiting stromal cells originally formed in the bone marrow. Previous research has shown that cancer-associated fibroblasts (CAFs), the most prominent stromal cell type, are highly prominent in breast tumors and their abundance was shown to correlate with...

Researchers Identify Protein that Makes Skin Cancer Cells More Invasive

Squamous cell carcinoma is a common type of skin cancer, usually affecting skin that is exposed to the damaging ultraviolet rays of the sun. Researchers have found that the loss of a protein that normally helps repair DNA called Tripartite Motif-Containing Protein 29 (TRIM29) promotes cancer cell invasion in a common type of skin cancer. Based on their results, they believe...

Patients Diagnosed with Adenomas may not Receive Colonoscopies in Recommended Time Frame

Results from a recent study presented in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR) and  funded by grants from the National Cancer Institute (NCI), shows that patients who are diagnosed with adenomas, a possible precursor of colorectal cancer, my not receive subsequent colonoscopies within the recommended time frame. "Adenomas are a...

DNA Origami – How a Tailored DNA Nanoplatform Carries Drugs to Multidrug-resistant Tumors

Multidrug resistance (MDR) is a major obstacle in the clinical treatment of patients with cancer. Down-regulation of genes responsible for drug resistance is one of the most successful techniques to combat multidrug-resistance in cancer cells. Chinese scientists have now developed a nanoplatform that selectively delivers small hairpin RNA transcription templates and chemotherapeutics agents into multidrug-resistant tumors. A deadly cocktail of gene-silencing...

Investigational Compound from Chinese Tree Bark Shows Potential as Treatment for Pancreatic Cancer

A new compound found in the bark of a rare Chinese tree, called FL118, has powerful anticancer properties and a low toxicity profile. This is what researchers at Roswell Park Comprehensive Cancer Center observed in a study funded by grants from the National Cancer Institute and by donations to Roswell Park The results of their study outlining the effect...

New Partnership Attacks Disparities in Cancer Outcomes

The National Cancer Institute (NCI) has awarded $2.17 million grant to develop a joint cancer drug discovery and development and research education program to focus on cancers that have increased risk of incidence and/or mortality among underserved communities, ethnic populations such as African-Americans, Latinos and Native Americans who bear a disproportionate burden of cancer compared with other groups The new...

Neoadjuvant Ipilimumab + Nivolumab Offers Potential to Change Standard of Care in Colon Cancer

According results reported at the annual congress of the European Society for Medical Oncology - ESMO 2018, held in Munich, Germany, October 19-23, 2018, the first exploratory phase II trial to investigate a neoadjuvant (pre-operative) treatment with a combination of the immune checkpoint inhibitors nivolumab (Opdivo®; Bristol-Myers Squibb Company) and ipilimumab (Yervoy®; Bristol-Myers Squibb Company) achieves major pathological responses...

Dana-Farber to Investigate New Therapy for Brain Cancer

Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, will collaborate with oncology-focused biotech company Kazia Therapeutics, an innovative oncology-focused biotechnology company, based in Sydney, Australia, to investigate the use of the company's potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain. The Phase II clinical study is designed to investigate...

Study of AXL Inhibitor DS-1205 in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Initiated

A first patient has been dosed in a first-in-human phase I study assessing the safety and tolerability of DS-1205, a highly selective investigational AXL inhibitor, in combination with gefitinib has been initiated in patients with metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have progressed on therapy with tyrosine kinase inhibitors (TKIs). A part...

Related articles